Eduardo Martins, president director of Pharlab, provides insights into the “2020 vision” that has been driving the eye-catching development of this ambitious domestic company and documents how Pharlab is leveraging the expertise and added value brought by France’s Biogaran, the company’s new owners, to sharpen its competitive advantage in the Brazilian market.
You have vast experience in the pharmaceutical industry. Could you walk us through the main milestones that led you to take over the helm of Pharlab in February 2017?
"At the moment, our objective is to aggressively develop our product portfolio through various sources, which includes bringing to Brazil different products from Biogaran’s portfolio as well as from external partnerships."
